Related Experiment Video

Updated: Jul 7, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Antithrombotic therapy in congestive heart failure]

Oliver Adam1, Michael Böhm

  • 1Klinik für Innere Medizin III, Kardiologie/Angiologie, Kirrberger Strasse, 66421 Homburg/Saar. o.adam@freenet.de

Herz
|February 15, 2008
PubMed

Insights

Patients with advanced chronic heart failure face higher risks of blood clots. This review clarifies when anticoagulant therapy is beneficial, offering guidance for severe left ventricular dysfunction.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Context:

  • Advanced chronic heart failure (CHF) and severe left ventricular dysfunction (LVD) significantly elevate thromboembolic complication risks.
  • Established indications for oral anticoagulation in CHF patients include prior thromboembolism, atrial fibrillation, or thrombosis.
  • Conflicting data exists regarding anticoagulation benefits in other CHF subgroups.

Purpose:

  • To review current data on thromboembolic risk in advanced CHF with severe LVD.
  • To evaluate the potential benefits of antithrombotic therapy in this patient population.
  • To provide updated recommendations for anticoagulant therapy in CHF patients.

Summary:

  • Patients with advanced chronic heart failure and severe left ventricular dysfunction have an increased risk of thromboembolic events.
  • While anticoagulation is indicated for specific conditions like prior thromboembolism or atrial fibrillation, its benefit in other patient subgroups remains unproven.
  • Existing research, including retrospective and randomized studies, presents conflicting evidence on the efficacy of chronic anticoagulation.

Impact:

  • Offers clinicians evidence-based guidance for managing anticoagulation in complex heart failure patients.
  • Aims to reduce thromboembolic complications and improve outcomes in severe CHF.
  • Highlights areas where further research is needed to clarify optimal antithrombotic strategies.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...